Why We’re Selling Editas Medicine Stock $EDIT

Описание: Editas Medicine stock $EDIT has not sunk below its IPO price of $16 a share. That’s after Editas stock peaked at $90 a share back in the heydays of #GeneEditing hype. Today, we’re holding shares after having gone long the first gene-editing stock to IPO. What attracted us to Editas in the first place was the high-profile founders who are considered to be pioneers in the gene-editing space. Editas is hanging their hat on two therapies, both of which are proceeding slowly. One, EDIT-301, is targeting diseases that #CRISPR Therapeutics is, and the latter is far ahead of Editas that plans to dose its first patient this year. Then there’s the constant turnover of C-level executives at Editas which makes us wonder if there aren’t some systemic problems that can’t be solved. As a result of our research, we’re moving out of Editas Medicine stock.

RESEARCH PIECES USED IN THIS VIDEO:
1. Why We’re Selling Editas Medicine Stock
https://www.nanalyze.com/2022/06/sell...
2. A Complete List of 27 Gene Editing Stocks
https://www.nanalyze.com/2022/06/comp...
3. What Do The Three Biggest Gene Editing Stocks Do?
https://www.nanalyze.com/2021/02/thre...

CHAPTERS:
00:00 Intro
01:31 Editas Medicine's lead therapies
02:25 EDIT-101 for eye disease
06:08 Allergan backs out
07:18 Editas' executive turnover issue
09:37 How EDIT-301 is way behind
11:22 The founders of Editas flee
13:08 Conclusion

ABOUT US:
This video is brought to you by Nanalyze, a boutique media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #investments in a language that is future-proof and easy to understand.

Read all the Nanalyze Premium articles you'd like for free! Sign up for a 30-day trial of our monthly subscription with no strings attached: https://www.nanalyze.com/become-a-nan...